<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Appl Basic Med Res</journal-id><journal-id journal-id-type="iso-abbrev">Int J Appl Basic Med Res</journal-id><journal-id journal-id-type="publisher-id">IJABMR</journal-id><journal-title-group><journal-title>International Journal of Applied and Basic Medical Research</journal-title></journal-title-group><issn pub-type="ppub">2229-516X</issn><issn pub-type="epub">2248-9606</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24083141</article-id><article-id pub-id-type="pmc">3783673</article-id><article-id pub-id-type="publisher-id">IJABMR-3-84</article-id><article-id pub-id-type="doi">10.4103/2229-516X.117056</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effect of sildenafil-induced nitric oxide on the histomorphology of cardiomyocytes in male rats</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Prabhu</surname><given-names>Latha V</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Rai</surname><given-names>Rajalakshmi</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Ranade</surname><given-names>Anu V</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Kini</surname><given-names>Hema</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Krishnamurthy</surname><given-names>Ashwin</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Bernhardt</surname><given-names>Kavitha Leigelin</given-names></name><xref ref-type="aff" rid="aff4">3</xref></contrib></contrib-group><aff id="aff1">Department of Anatomy, Kasturba Medical College, Manipal University, Mangalore, Karnataka, India</aff><aff id="aff2"><label>1</label>Department of Anatomy, Gulf Medical University, Ajman, United Arab Emirates</aff><aff id="aff3"><label>2</label>Department of Pathology, Kasturba Medical College, Manipal University, Mangalore, Karnataka, India</aff><aff id="aff4"><label>3</label>Department of Physiology, Kasturba Medical College International Center, Manipal University, Manipal, Karnataka, India</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Rajalakshmi Rai, Department of Anatomy, Kasturba Medical College, Bejai, Mangalore - 576 104, Karnataka, India. E-mail: <email xlink:href="rajalakshmi.rai@manipal.edu.">rajalakshmi.rai@manipal.edu.</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Dec</season><year>2013</year></pub-date><volume>3</volume><issue>2</issue><fpage>84</fpage><lpage>87</lpage><history><date date-type="received"><day>25</day><month>10</month><year>2012</year></date><date date-type="accepted"><day>12</day><month>3</month><year>2013</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; International Journal of Applied and Basic Medical Research</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Introduction:</title><p>Although sildenafil citrate, one of the selective phosphodiesterase-5 (PDE5) inhibitors, is considered the best treatment for erectile dysfunction, studies have shown that it has also a beneficial effect on a variety of cardiovascular conditions. In spite of reports of a significant protective effect of sildenafil against necrosis in intact hearts, there are also contradictory reports regarding its beneficial effect on the heart. Since there are not enough reports regarding the histomorphological changes in the cardiomyocytes after exposure to sildenafil citrate, the present study was conducted to observe the same along with other biochemical parameters.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>Adult male albino rats of Wistar strain were used in the present study. The animals were divided into a control group and two experimental groups containing six rats each. The animals were treated with a solution of sildenafil citrate dissolved in distilled water. Histomorphological changes were observed by light microscopy and the levels of nitric oxide (NO) and PDE in the heart were measured by spectrophotometry.</p></sec><sec id="st3"><title>Results:</title><p>It was observed that animals treated with sildenafil citrate showed a highly significant increase in NO and a decrease in PDE level, but the histological architecture of the cardiomyocytes did not show much change other than a slightly elongated and swollen nucleus.</p></sec><sec id="st4"><title>Conclusions:</title><p>This study shows that sildenafil citrate at low dosage is well tolerated by cardiac muscle cells, but as dosage increases, it may become detrimental through its NO and PDE activity.</p></sec></abstract><kwd-group><kwd>Cardiomyocytes</kwd><kwd>erectile dysfunction</kwd><kwd>nitric oxide</kwd><kwd>phosphodiesterase-5 inhibitor</kwd><kwd>sildenafil</kwd></kwd-group></article-meta></front><body><sec id="sec1-1"><title>I<sc>NTRODUCTION</sc></title><p>Among all phosphodiesterase-5 (PDE5) inhibitors sildenafil citrate is considered one of the prize-winning because of its efficacy[<xref ref-type="bibr" rid="ref1">1</xref><xref ref-type="bibr" rid="ref2">2</xref><xref ref-type="bibr" rid="ref3">3</xref><xref ref-type="bibr" rid="ref4">4</xref>] and pleiotropic effects.[<xref ref-type="bibr" rid="ref5">5</xref>] Also in recent years, there have been several studies on sildenafil for its therapeutic applications in diseases other than erectile dysfunction (ED).[<xref ref-type="bibr" rid="ref6">6</xref><xref ref-type="bibr" rid="ref7">7</xref><xref ref-type="bibr" rid="ref8">8</xref><xref ref-type="bibr" rid="ref9">9</xref><xref ref-type="bibr" rid="ref10">10</xref><xref ref-type="bibr" rid="ref11">11</xref><xref ref-type="bibr" rid="ref12">12</xref>] Kumar <italic>et al</italic>.,[<xref ref-type="bibr" rid="ref13">13</xref>] stated that patients with heart failure and preserved ejection fraction might derive particular benefit from these drugs. However, unfortunately, as the availability of sildenafil has become easier, it is being used and misused by many.[<xref ref-type="bibr" rid="ref14">14</xref>] Reports in letters to the Editor of the <italic>British Medical Journal</italic> state that sildenafil is used as a recreational drug in younger generations.[<xref ref-type="bibr" rid="ref15">15</xref>] On account of the increasing incidences of sudden cardiac deathsamong ED patients treated with sildenafil citrate, it becomes essential to understand how this drug affects the heart. Therefore the present study was conducted to find out the histological changes in the cardiomyocytes and correlate it with the biochemical parameters.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>M<sc>ATERIALS AND</sc> M<sc>ETHODS</sc></title><p>Adult (14-16 weeks old) male albino rats of Wistar strain were used in the present study. The animals were divided into two groups. Group-I (control group (<italic>n</italic> = 6)) rats were intraperitoneally injected distilled water for the duration of the experiment on alternate days. Group-1a and1b (experimental groups (<italic>n</italic> = 6 in each group)) rats were intraperitoneally injected 10 mg/kg body weight (bw) and 8 mg/kg bw of sildenafil citrate, respectively, for 30 days, on every alternate day at a regular time interval. The dosing solution was prepared by grinding Viagra tablets into powder and dissolving in distilled water (concentration: 3.5 mg/ml of water).[<xref ref-type="bibr" rid="ref16">16</xref><xref ref-type="bibr" rid="ref17">17</xref>] On the last day of the treatment, rats were anaesthetized with pentobarbital sodium (45 mg/kg bw) 1 h after injecting sildenafil citrate. The experimental protocol was approved by the Institutional Animal Ethics Committee of Manipal University (Vide No.: 245/2005). The heart was removed from the killed rats and part of the left ventricle was used for histopathological analysis and the other part for biochemical investigations.</p><p>The part of the tissue for histological analysis was fixed in 10% formalin for 18 h. Following fixation, the specimens were dehydrated, embedded and then sectioned to 5 &#x003bc;m thickness. For histological examinations, sections were stained with Ehrlich hematoxylin and eosin.[<xref ref-type="bibr" rid="ref18">18</xref>] Multiple slides were examined for each group: At least three slides from different areas of the tissue were examined. Each tissue was examined with a standard light microscope.</p><p>Tissue for biochemical estimation was homogenated in 10 ml of phosphate-buffered saline (pH 7.4). The homogenate was tested for nitric oxide (NO) and PDE. NO was estimated by Griess reagent method[<xref ref-type="bibr" rid="ref19">19</xref>] and PDEwas measured by spectrophotometry.[<xref ref-type="bibr" rid="ref20">20</xref><xref ref-type="bibr" rid="ref21">21</xref>]</p><sec id="sec2-1"><title>Data analysis</title><p>Results are expressed as means &#x000b1; standard deviation (SD). Kruskal &#x02013; Wallis test was performed to measure any differences between the mean values of the different groups. If a difference was found, groups were compared using Wilcoxon signed rank sum test. Probability value (<italic>P</italic>-value) less than 0.05 was considered significant.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>R<sc>ESULTS</sc></title><sec id="sec2-2"><title>Results of biochemical analysis</title><sec id="sec3-1"><title>NO level</title><p>Animals in Group-Ia showed a highly significant (<italic>P</italic> &#x0003c; 0.05) increase and those in Group-Ib showed a significant (<italic>P</italic> &#x0003c; 0.01) increase in the level of NO in the heart when compared with their control group (Group-I) [<xref ref-type="table" rid="T1">Table 1</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>NO level in heart in the control and experimental groups</p></caption><graphic xlink:href="IJABMR-3-84-g001"/></table-wrap></sec><sec id="sec3-2"><title>PDE level</title><p>There was a highly significant decrease (<italic>P</italic> &#x0003c; 0.01) in the level of PDE in the heart of animals in Group-Ia in comparison with the control group, whereas changes in PDE level in Group-Ib animals were not significant when compared with those in the control group animals [<xref ref-type="table" rid="T1">Table 1</xref>].</p></sec></sec><sec id="sec2-3"><title>Results of histological analysis of heart</title><p>Histological evaluation of heart sections from animals of Group-Ia showed a few morphological changes in their microstructure. The nucleus of the muscle fibers in this group was slightly swollen and elongated. In Group-Ib animals the cardiac muscles did not show any morphological changes in their microstructure when compared with the control group animals.</p></sec></sec><sec sec-type="discussion" id="sec1-4"><title>D<sc>ISCUSSION</sc></title><p>Although studies of intact hearts have demonstrated a significant protective effect of sildenafil against necrosis (infarction), there is absolutely no information in the literature regarding the histological changes in cardiomyocytes. After an early case report suggesting that PDE5A inhibitors might increase the risk of heart attack,[<xref ref-type="bibr" rid="ref22">22</xref>] several studies attemptedto define the cardiac effects of this class of drugs. Results of direct analysis of cardiac effects, which have been obtained <italic>in vitro</italic>, remain limited and conflicting. It is said that PDE1 is abundant in ventricular myocytes and sildenafil shows far less affinity for other PDE isozymes, including PDE1.[<xref ref-type="bibr" rid="ref23">23</xref>] There has been a dominant view that PDE5 is not present in the myocardium.[<xref ref-type="bibr" rid="ref23">23</xref><xref ref-type="bibr" rid="ref24">24</xref>] Cheitlin <italic>et al</italic>.,[<xref ref-type="bibr" rid="ref24">24</xref>] stated that PDE5 is not present in cardiomyocytes, instead PDE3 is found and sildenafil is comparatively less potent on this isoenzyme.[<xref ref-type="bibr" rid="ref24">24</xref>] The present study shows that changes in the level of total PDE were statistically significant at a dosage of 10 mg/kg bw when compared with the 8-mg/kg bw and the control groups. This suggests that as the dosage of sildenafil increases it becomes more potent on PDE in heart, indicating the presence of PDE5. This is in agreement with the results of a few previous studies, which showed that PDE5 is found in specific compartments within myocytes (specifically at z-bands).[<xref ref-type="bibr" rid="ref17">17</xref><xref ref-type="bibr" rid="ref25">25</xref>] Cremers <italic>et al</italic>.,[<xref ref-type="bibr" rid="ref26">26</xref>] found no effect of 10 &#x003bc;M sildenafil (a relatively high dose) on isoprenaline-stimulated function in human papillary muscle strips. PDE5 inhibition has also been shown to suppress and reverse pressure over-load-induced ventricular hypertrophy,[<xref ref-type="bibr" rid="ref27">27</xref>] attenuate apoptosis[<xref ref-type="bibr" rid="ref17">17</xref>] and reduce post-ischemic dysfunction[<xref ref-type="bibr" rid="ref28">28</xref>] in mice, which appear to be critically coupled to the NO synthase. In the present study, at 8 mg/kg bw cardiomyocytes did not show any histological changes, indicating the negligible effect of sildenafil citrate on the heart at a low dosage. However, as dosage increased (10 mg/kg bw) the nucleus of the cardiac muscle became swollen and elongated. Tracqui <italic>et al</italic>.,[<xref ref-type="bibr" rid="ref29">29</xref>] have described the death of a 56-year-old man associated from an overdose of sildenafil citrate. Histological examination of the ventricular myocardium revealed some areas of patchy fibrosis and moderate hypertrophy of the myocytes.</p><p>Fisher <italic>et al</italic>.,[<xref ref-type="bibr" rid="ref28">28</xref>] hypothesized that the vasodilatory action of sildenafil could potentially release endogenous mediators of preconditioning such as adenosine or bradykinin from endothelial cells, triggering the phosphorylation of NO synthase (NOS) and subsequent release of NO. If the increased production of NO is well in balance with a moderate increase in oxygen radicals then NO will exert beneficial effects.[<xref ref-type="bibr" rid="ref30">30</xref>] In the present study, although there was significantly high (<italic>P</italic> &#x0003c; 0.05) level of NO when compared with the control group at a high dosage (10mg/kg bw), histological differences were fewerthan the control group animals [<xref ref-type="fig" rid="F1">Figure 1</xref>]. Therefore it can be concluded that sildenafil citrate at a low dosage does not appear to influence cardiomyocytes. However, NO-induced changes may become detrimental to the cardiac tissue as the dosage of the sildenafil increases.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Photomicrographs of cardiac muscle tissue. Magnification: (H and E, &#x000d7;40). Control: Animals treated with distilled water. (a) Group-Ia (10 mg/kg bw sildenafil citrate). (b) Group-Ib (8 mg/kg bw sildenafil citrate); N: Nucleus of cardiomyocytes; F: Fibrocytes</p></caption><graphic xlink:href="IJABMR-3-84-g002"/></fig></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>R<sc>EFERENCES</sc></title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>PJ</given-names></name></person-group><article-title>Comparison of phosphodiesterase type 5 (PDE5) inhibitors</article-title><source>Int J Clin Pract</source><year>2006</year><volume>60</volume><fpage>967</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">16780568</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cirino</surname><given-names>G</given-names></name><name><surname>Fusco</surname><given-names>F</given-names></name><name><surname>Imbimbo</surname><given-names>C</given-names></name><name><surname>Mirone</surname><given-names>V</given-names></name></person-group><article-title>Pharmacology of erectile dysfunction in man</article-title><source>Pharmacol Ther</source><year>2006</year><volume>111</volume><fpage>400</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">16443277</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnett</surname><given-names>AL</given-names></name></person-group><article-title>Phosphodiesterase 5 mechanisms and therapeutic applications</article-title><source>Am J Cardiol</source><year>2005</year><volume>96</volume><fpage>29</fpage><lpage>31M</lpage></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seftel</surname><given-names>AD</given-names></name></person-group><article-title>Phosphodiesterase type 5 inhibitors: Molecular pharmacology and interactions with other phosphodiesterases</article-title><source>Curr Pharm Des</source><year>2005</year><volume>11</volume><fpage>4047</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">16378510</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlachopoulos</surname><given-names>C</given-names></name><name><surname>Ioakeimidis</surname><given-names>N</given-names></name><name><surname>Rokkas</surname><given-names>K</given-names></name><name><surname>Stefanadis</surname><given-names>C</given-names></name></person-group><article-title>Cardiovascular effects of phosphodiesterase type 5 inhibitors</article-title><source>J Sex Med</source><year>2009</year><volume>6</volume><fpage>658</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">19138362</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrams</surname><given-names>D</given-names></name><name><surname>Schulze-Neick</surname><given-names>I</given-names></name><name><surname>Magee</surname><given-names>AG</given-names></name></person-group><article-title>Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension</article-title><source>Heart</source><year>2000</year><volume>84</volume><fpage>e4</fpage><pub-id pub-id-type="pmid">10908271</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>S</given-names></name><name><surname>Wilkinson</surname><given-names>J</given-names></name><name><surname>Gatzoulis</surname><given-names>MA</given-names></name></person-group><article-title>Sildenafil primary pulmonary hypertension</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>1342</fpage><pub-id pub-id-type="pmid">11183578</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkens</surname><given-names>H</given-names></name><name><surname>Guth</surname><given-names>A</given-names></name><name><surname>Konig</surname><given-names>J</given-names></name><name><surname>Forestier</surname><given-names>N</given-names></name><name><surname>Cremers</surname><given-names>B</given-names></name><name><surname>Hennen</surname><given-names>B</given-names></name><etal/></person-group><article-title>Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension</article-title><source>Circulation</source><year>2001</year><volume>104</volume><fpage>1218</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">11551870</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Tsang</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats</article-title><source>Stroke</source><year>2002</year><volume>33</volume><fpage>2675</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">12411660</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michelakis</surname><given-names>E</given-names></name><name><surname>Tymchak</surname><given-names>W</given-names></name><name><surname>Lien</surname><given-names>D</given-names></name><name><surname>Webster</surname><given-names>L</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name><name><surname>Archer</surname><given-names>S</given-names></name></person-group><article-title>Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide</article-title><source>Circulation</source><year>2002</year><volume>105</volume><fpage>2398</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">12021227</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sebkhi</surname><given-names>A</given-names></name><name><surname>Strange</surname><given-names>JW</given-names></name><name><surname>Phillips</surname><given-names>SC</given-names></name><name><surname>Wharton</surname><given-names>J</given-names></name><name><surname>Wilkins</surname><given-names>MR</given-names></name></person-group><article-title>Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension</article-title><source>Circulation</source><year>2003</year><volume>107</volume><fpage>3230</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">12796132</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reffelmann</surname><given-names>T</given-names></name><name><surname>Kloner</surname><given-names>RA</given-names></name></person-group><article-title>Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease</article-title><source>Circulation</source><year>2003</year><volume>108</volume><fpage>239</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">12860892</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Francis</surname><given-names>GS</given-names></name><name><surname>Tang</surname><given-names>WH</given-names></name></person-group><article-title>Phosphodiesterase 5 inhibition in heart failure: Mechanisms and clinical implications</article-title><source>Nat Rev Cardiol</source><year>2009</year><volume>6</volume><fpage>349</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">19377497</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enomoto</surname><given-names>M</given-names></name><name><surname>Sakaguchi</surname><given-names>H</given-names></name><name><surname>Ominami</surname><given-names>M</given-names></name><name><surname>Iwai</surname><given-names>S</given-names></name><name><surname>Morikawa</surname><given-names>H</given-names></name><name><surname>Tamori</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sildenafil-induced severe cholestatic hepatotoxicity</article-title><source>Am J Gastroenterol</source><year>2009</year><volume>104</volume><fpage>254</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">19098889</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldridge</surname><given-names>J</given-names></name><name><surname>Measham</surname><given-names>F</given-names></name></person-group><article-title>Sildenafil (Viagra) is used as a recreational drug in England</article-title><source>BMJ</source><year>1999</year><volume>318</volume><fpage>669</fpage><pub-id pub-id-type="pmid">10066221</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behn</surname><given-names>D</given-names></name><name><surname>Potter</surname><given-names>MJ</given-names></name></person-group><article-title>Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the gamma-subunit of phosphodiesterase</article-title><source>Invest Ophthalmol Vis Sci</source><year>2001</year><volume>42</volume><fpage>523</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11157892</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Xi</surname><given-names>L</given-names></name><name><surname>Kukreja</surname><given-names>RC</given-names></name></person-group><article-title>Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of NO signaling</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>12944</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15668244</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>A</given-names></name><name><surname>Wilson</surname><given-names>I</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Bancroft</surname><given-names>JD</given-names></name><name><surname>Stevens</surname><given-names>A</given-names></name><name><surname>Turner</surname><given-names>DR</given-names></name></person-group><article-title>The haematoxylins and eosin</article-title><source>Theory and Practice of Histological Techniques</source><year>1996</year><edition>4th ed</edition><publisher-loc>Hong Kong</publisher-loc><publisher-name>Churchill Livingstone</publisher-name><fpage>99</fpage><lpage>112</lpage></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>AH</given-names></name><name><surname>Nathan</surname><given-names>CF</given-names></name><name><surname>Stuehr</surname><given-names>DJ</given-names></name></person-group><article-title>Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: Comparison of activating cytokines and evidences for independent production</article-title><source>J Immunol</source><year>1988</year><volume>141</volume><fpage>2407</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">3139757</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razzell</surname><given-names>WE</given-names></name><name><surname>Khorana</surname><given-names>HG</given-names></name></person-group><article-title>Studies on polynucleotides. IV. Enzymic degradation. The stepwise action of venom phosphodiesterase on deoxyribo-oligonucleotides</article-title><source>J Biol Chem</source><year>1959</year><volume>234</volume><lpage>2114</lpage></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mamillapalli</surname><given-names>R</given-names></name><name><surname>Haimovitz</surname><given-names>R</given-names></name><name><surname>Ohad</surname><given-names>M</given-names></name><name><surname>Shinitzky</surname><given-names>M</given-names></name></person-group><article-title>Enhancement and inhibition of snake venom phosphodiesterase activity by lysophospholipids</article-title><source>FEBS Lett</source><year>1998</year><volume>436</volume><fpage>256</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9781690</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feenstra</surname><given-names>J</given-names></name><name><surname>van Drie-Pierik</surname><given-names>RJ</given-names></name><name><surname>Lacle</surname><given-names>CF</given-names></name><name><surname>Stricker</surname><given-names>BH</given-names></name></person-group><article-title>Acute myocardial infarction associated with sildenafil</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>957</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9752820</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallis</surname><given-names>RM</given-names></name><name><surname>Corbin</surname><given-names>JD</given-names></name><name><surname>Francis</surname><given-names>SH</given-names></name><name><surname>Ellis</surname><given-names>P</given-names></name></person-group><article-title>Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculaecarneae and aortic rings <italic>in vitro</italic></article-title><source>Am J Cardiol</source><year>1999</year><volume>83</volume><fpage>3</fpage><lpage>12C</lpage></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheitlin</surname><given-names>MD</given-names></name><name><surname>Hutter</surname><given-names>AM</given-names></name><name><surname>Brindis</surname><given-names>RG</given-names></name><name><surname>Ganz</surname><given-names>P</given-names></name><name><surname>Kaul</surname><given-names>S</given-names></name><name><surname>Russell</surname><given-names>RO</given-names></name></person-group><article-title>Use of sildenafil (Viagra) in patients with cardiovascular disease</article-title><source>Circulation</source><year>1999</year><volume>99</volume><fpage>168</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">9884398</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takimoto</surname><given-names>E</given-names></name><name><surname>Champion</surname><given-names>HC</given-names></name><name><surname>Belardi</surname><given-names>D</given-names></name><name><surname>Moslehi</surname><given-names>J</given-names></name><name><surname>Mongillo</surname><given-names>M</given-names></name><name><surname>Mergia</surname><given-names>E</given-names></name><etal/></person-group><article-title>cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism</article-title><source>Circ Res</source><year>2005a</year><volume>96</volume><fpage>100</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15576651</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cremers</surname><given-names>B</given-names></name><name><surname>Scheler</surname><given-names>M</given-names></name><name><surname>Maack</surname><given-names>C</given-names></name><name><surname>Wendler</surname><given-names>O</given-names></name><name><surname>Schafers</surname><given-names>HJ</given-names></name><name><surname>Sudkamp</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of sildenafil (Viagra) on human myocardial contractility, <italic>in vitro</italic> arrhythmias, and tension of internal mammaria arteries and saphenous veins</article-title><source>J Cardiovasc Pharmacol</source><year>2003</year><volume>41</volume><fpage>734</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">12717104</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takimoto</surname><given-names>E</given-names></name><name><surname>Champion</surname><given-names>HC</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Belardi</surname><given-names>D</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Rodriguez</surname><given-names>ER</given-names></name><etal/></person-group><article-title>Chronic inhibition of cGMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy</article-title><source>Nat Med</source><year>2005</year><volume>11</volume><fpage>214</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">15665834</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>PW</given-names></name><name><surname>Salloum</surname><given-names>F</given-names></name><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Hyder</surname><given-names>H</given-names></name><name><surname>Kukreja</surname><given-names>RC</given-names></name></person-group><article-title>Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity</article-title><source>Circulation</source><year>2005</year><volume>111</volume><fpage>1601</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">15811867</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tracqui</surname><given-names>A</given-names></name><name><surname>Miras</surname><given-names>A</given-names></name><name><surname>Tabib</surname><given-names>A</given-names></name><name><surname>Raul</surname><given-names>JS</given-names></name><name><surname>Ludes</surname><given-names>B</given-names></name><name><surname>Malicier</surname><given-names>D</given-names></name></person-group><article-title>Fatal overdosage with sildenafil citrate (Viagra): First report and review of the literature</article-title><source>Hum Exp Toxicol</source><year>2002</year><volume>21</volume><fpage>623</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12507258</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berges</surname><given-names>A</given-names></name><name><surname>Van Nassauw</surname><given-names>L</given-names></name><name><surname>Bosmans</surname><given-names>J</given-names></name><name><surname>Timmermans</surname><given-names>JP</given-names></name><name><surname>Vrints</surname><given-names>C</given-names></name></person-group><article-title>Role of nitric oxide and oxidative stress in ischaemic myocardial injury and preconditioning</article-title><source>Acta Cardiol</source><year>2003</year><volume>58</volume><fpage>119</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">12715903</pub-id></element-citation></ref></ref-list></back></article>